No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CTLT240517P52500
- 0.05
- -0.07-58.33%
15min DelayClose May 3 12:30 ET
0.05High0.05Low
0.05Open0.12Pre Close30 Volume1.17K Open Interest52.50Strike Price150.00Turnover23.76%IV-7.17%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.0463Delta0.0379Gamma1130.00Leverage Ratio-0.0087Theta-0.0008Rho-52.37Eff Leverage0.0105Vega
Intraday
- 5D
- 1D
News
Health Care Climbs as Amgen Surges on Obesity-Drug Plans - Health Care Roundup
Health-care companies rose after a surprising new entrant in the obesity-drug bonanza from one biotech giant. Amgen shares surged after the biotech giant said it saw encouraging signs from its inject
Top Midday Stories: Apple's Dividend, Buybacks Announcements; Amgen Obesity Drug Trial Results; Exxon Completes Pioneer Acquisition
Wall Street's major indexes all jumped on the heels of a softer-than-expected jobs report released Friday by the US Department of Labor. In company news, Apple (AAPL) reported fiscal Q2 diluted earnin
Catalent, Novo Nordisk Antitrust Review Extended by FTC
Catalent (CTLT) said Friday the US Federal Trade Commission is asking for more information while the agency reviews the proposed acquisition of the biologics and gene therapies company by Danish drug
UPDATE 1-US FTC Seeks More Information on Novo Nordisk Parent-Catalent Deal
Express News | Catalent Inc - Catalent and Novo Holdings Expect to Close Merger Towards End of Calendar Year 2024
Express News | Catalent Inc - Intend to Continue to Cooperate With FTC in an Effort to Obtain Antitrust Regulatory Clearance for Merger as Expeditiously as Possible
Comments
ColumnsEli Lilly's Donanemab Nears Approval Decision, Could This Be a Turning Point in Alzheimer's Treatment?
The pharma giant $Eli Lilly and Co(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
70
$Catalent(CTLT.US$ why drop
$Catalent(CTLT.US$ 👀63$ all set target
ColumnsWall Street Today | Stocks Retreat as Fed in No Rush to Cut
RECAP
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
23
2
Read more